NEWS

New research fellowship explores pediatric headache treatment

Two students at the UMKC School of Medicine have received a new award from the Children’s Mercy Hospital Philanthropy Fund to support research interests in neurology. Dane Stephens, a fourth-year

UMKC researchers to present late-breaking studies at cardiovascular symposium

Research studies by UMKC School of Medicine faculty researchers at the Saint Luke’s Mid America Heart Institute have been selected for presentation at the world’s largest educational meeting for interventional

Brain tumor research follows unusual path

A promising therapy to combat brain tumors in children has emerged from a confluence of bold research, scientific insight and luck, a Children’s Mercy research director said Aug. 30 in

Faris receives UMKC Project ADVANCER award

Third-year medical student Hunter Faris has been selected for a student research award from the UMKC strategic funding award initiative, Project ADVANCER (Academic Development Via Applied aNd Cutting-Edge Research). The

More News

EVENTS

Nov
20
Mon
Ophthalmology IG – Research in Ophthalmology with Dr. Komal Desai
Nov 20 @ 5:30 pm – 6:30 pm
Nov
23
Thu
Thanksgiving Day Holiday – University Holiday – University offices are closed.
Nov 23 – Nov 24 all-day
Nov
27
Mon
SNMA – Health through the Eyes of Culture
Nov 27 @ 6:00 pm – 7:30 pm
Nov
29
Wed
Health Sciences Deans’ Seminar Series – John Q. Wang, M.D., Ph.D.
Nov 29 @ 12:00 pm – 1:00 pm
Nov
30
Thu
Interpreting PFTS – Pulmonary/CC IG
Nov 30 @ 4:30 pm – 6:00 pm


View Calendar

Research at the School of Medicine

At the School of Medicine, research plays a critical role in medical education. Here, faculty not only teach the techniques and approaches used in medical studies and investigations, they are making significant advances through conducting their own cutting-edge biomedical research. And students regularly are recognized and honored for their research presentations at various regional, national and international conferences. Together, these efforts make UMKC a growing leader in research excellence.

Biomedical & Health Informatics

More Info

Biomedical and Health Informatics

Affiliated Faculty

Photo of Thomas M. Attard, M.D.
Thomas M. Attard, M.D.
Associate Professor, University of Missouri-Kansas City Children’s Mercy HospitalPediatrics
More Info

Research Interests
  • Metadata analysis of gastrointestinal hemorrhage and other adverse endoscopy outcomes.
  • Hereditary polyposis syndrome related colectomy in children – morbidity and mortality



Photo of Mary M. Gerkovich, Ph.D.
Mary M. Gerkovich, Ph.D.
Associate Professor Office for Health Services & Outcomes ResearchDepartment of Biomedical & Health Informatics
  • 1998 – University of Kansas
More Info

Research Interests

Evaluation of a botanical product for use with osteoarthritis patients.

Identifying methods and resources to support HIV+ patients for maintaining engagement in care and self-management.

Projects using large secondary datasets to address issues related to health conditions and care.


Photo of Mark Hoffman, Ph.D.
Mark Hoffman, Ph.D.
Department of Biomedical & Health Informatics

 

  • Research Associate Professor – Biomedical & Health Informatics
  • ResearchAssociate Professor – Pediatrics
  • Children’s Mercy Hospital – Director Translational Bioinformatics
More info

Biography

Dr. Mark Hoffman received his Ph.D. from the University of Wisconsin – Madison and performed post-doctoral research at the National Animal Disease Center in Ames, Iowa. Before joining UMKC, he spent 16 years leading genomics, public health and research initiatives at Cerner Corporation, where he was a Vice President. In addition to his peer-reviewed publications, Mark is an inventor on 16 issued patents.

Research Interests

CDC funded use of laboratory and medical data warehouses to support quality improvement.

Pharmacogenomic knowledge representation and decision support.

Influence of patient context on health, what I refer to as the ‘Envirome’.

View CV



Photo of Peter Koulen, Ph.D.
Peter Koulen, Ph.D.
Departments of Ophthalmology & Biomedical Sciences Work Phone: (816) 404-1824

Professor and Felix and Carmen Sabates Missouri Endowed Chair in Vision Research
Director of Basic Research, Vision Research Center
Department of Ophthalmology

Professor
Department of Biomedical Sciences

More info

Research Interest

Dr. Koulen is a Professor of Ophthalmology and Biomedical Sciences and the Felix and Carmen Sabates Missouri Endowed Chair in Vision Research at the UMKC School of Medicine. He trained at the Max-Planck-Institute for Brain Research, Yale University and the Marine Biological Laboratory. His research focuses on basic research on and therapy development for chronic diseases of the eye and brain. He is an internationally recognized expert in biophysics, biochemistry and physiology of nerve cells and his research has been funded continually since 2002 by national and international foundations and agencies including the NIH’s National Eye Institute, National Institute on Aging, National Cancer Institute, National Center for Research Resources, National Institute of Diabetes and Digestive and Kidney Diseases, and the U.S. DOD among others. As principal or co-investigator for over $20 million in extramural grant funding for research studies, Dr. Koulen’s research program has fundamental relevance to basic science, translational research and therapy development as evidenced by over 120 peer-reviewed publications in scientific journals, and 10 book chapters. Dr. Koulen has over 25 years of experience in the fields of neuroscience and eye research, drug development, translational research, biological sciences, biostatistics, and routinely interprets complex data sets with distinct public health significance. Dr. Koulen serves as reviewer for more than 50 professional scientific journals, serves on over 15 editorial boards and is editor in chief of two scientific journals. He is a review panel member for several national and international funding agencies including the National Science Foundation, the National Institutes of Health, the U.S. Department of Defense and other national and international government agencies and research foundations. The University of Missouri – Kansas City Board of Trustees recognized Dr. Koulen with the N.T. Veatch Award for Distinguished Research and Creativity. Through this Faculty Award, UMKC and the UMKC Trustees are recognizing the very best faculties, who have distinguished themselves through scholarship and creativity.

Vision research

Degeneration or acute damage of nerve cells in the retina is a major cause of visual loss and blindness in the United States and worldwide. As diseases such as glaucoma, macular degeneration and diabetic retinopathy affect significant and increasing portions of the U.S. population, including minorities affected by disparities in health care delivery, determining causes, mechanisms of action and subsequently potential treatment strategies will contribute to improving health care, health and performance requiring visual tasks.

The Vision Research Center was founded as and is a well-established collaboration of several UMKC schools and Kansas City Medical Centers and thus offers an unprecedented interdisciplinary synergy with a unified goal: to better diagnose, prevent, and treat eye disease and vision disorders through translational research in order to make a difference in the lives of tens of millions of people worldwide. To this end, the center conducts federally and industry funded basic, translational and clinical research to develop new medical therapies and offers patient care in all subspecialties of ophthalmology. The center’s nationally recognized excellence in research, patient care and medical education contribute to UMKC’s strengths in the life sciences. Objectives of the Vision Research Center are to:

  • Provide a direct avenue for basic and translational research in eye and related diseases,
  • Transfer basic science findings seamlessly into practical use with patients through translational research,
  • Develop new therapy approaches urgently needed by physicians in the US and worldwide,
  • Provide educational excellence,
  • Ensure patients receive the most advanced medical treatments available,
  • Become a national center of excellence for eye research.
Publications:

My NCBI Collections


Matthew McLaughlin, M.D.
Assistant Professor Children’s Mercy Hospital
More Info

Research Interests

I am willing to tailor projects to meet the needs of students; however, they should be in my discipline of Pediatric or Adult Physical Medicine and Rehabilitation. Some unique areas of interest are: Cerebral palsy Clinical pharmacology Spasticity management Adaptive sports Disability populations Concussion Traumatic brain or spinal cord injury.


Photo of Cy B. Nadler, Ph.D.
Cy B. Nadler, Ph.D.
Assistant Professor, University of Missouri-Kansas City Children’s Mercy HospitalPediatrics
More Info

Research Interests

I lead multiple research projects in the areas of Autism Spectrum Disorders and Developmental Disabilities: One series of projects is focused on autism and developmental screening in primary care medical settings. We have an ongoing quality improvement initiate at Children’s Mercy, which has yielded a large health database. We have use this database for additional projects related to health disparities and health outcomes related to screening. I am interested in research related to parenting and autism/developmental disabilities, health care access, health & treatment outcomes, dissemination, and the education and training of healthcare professionals about developmental disabilities. Finally, I am the site PI for a large epidemiological study on autism and developmental disabilities funded by the Centers for Disease Control.


Mark Patterson, Ph.D., M.P.H.
Associate Professor UMKC School of Pharmacy
More info

Research Interests

1) Using mixed methods approaches to examine the prevalence of medication discrepancies and their underlying workflow attributed to those discrepancies that occurring during transitions of care between hospitals and nursing homes in rural Missouri. 2) Proposal currently under review to use the HealthFacts dataset to estimate the prevalence and patterns of antipsychotic polypharmacy prescribing patterns present in patients hospitalized with schizophrenia.


Photo of Shui Qing Ye, M.D., Ph.D.
Shui Qing Ye, M.D., Ph.D.
Professor & the William R. Brown / Missouri Endowed Chair Medical Genetics & Molecular MedicineDepartment of Biomedical & Health Informatics
  • 1993, PhD, University of Chicago Pritzker School of Medicine, Chicago IL
  • 1982, Doctor of Medicine, Wuhan University School of Medicine, Wuhan China
More Info

Research Interests

Investigate the roles and molecular mechanisms of nicotinamide phosphoribosyltransferase in acute respiratory distress syndrome, arthritis, drug induced liver injury.

Identify new genetic risk factors underlying complex diseases using next generation DNA sequencing technologies.

Apply Translational Bioinformatics to leverage ‘Big Data’ to make new biological discoveries and gain new unifying global biological insights, which may lead to the development of new diagnostic and therapeutic targets for human diseases.


Photo of Nilofer Qureshi, Ph.D.
Nilofer Qureshi, Ph.D.
Director – Molecular & Cellular Immunology, Professor Immunology Work MG-CO5E Home Phone: (816) 235-1965
  • Ph. D. in Physiological Chemistry, Medical School, University of Wisconsin, Madison, WI
More info

Research Interests:

To develop novel therapeutic approaches to treat septic shock and inflammation.

We were the first to establish the complete structure of the lipid A moiety of the enterobacterial lipopolysaccharide (LPS), developed monophosphoryl lipid A as an effective adjuvant and Rhodobacter sphaeroides diphosphoryl lipid A as a powerful LPS antagonist in both in vitro and in vivo systems. Our recent research centers on the biology of LPS, especially, with regards to its effect on the ubiquitin-proteasome pathway (UPP) in macrophages and septic shock. We initially demonstrated that the LPS-induced cytokines are dependent on the composition of proteasome’s subunits present in the macrophages. We are working on a novel therapeutic approach for septic shock based upon proteasome inhibitors and antibiotics. We are also establishing the identity of ubiquitinated proteins in the LPS-induced signal transduction that are degraded by the proteasome in murine macrophages and human cells. Our conclusion from these studies is that the proteasome is a central regulator of macrophage function and inflammation and is involved in several diseases such as septic shock, cardiovascular problems, cancer and asthma.

 

Selected Publications : out of a total of over 130

Qureshi N, Perera P-Y, Shen J, Zhang G, Lenschat A, Spptter G, Morrison DC, Vogel SN. The proteasome as a LPS-binding protein in macrophages: Differential effects of proteasome inhibition on LPS-induced events. J Immunol. 2003, 171:1515-1525.

Qureshi N, Vogel SN, Van Way III, Papasian C, Qureshi AA, Morrison DC. The proteasome, a central regulator of Inflammation and macrophage function. Immunologic Research 2005, 31/3:243-260.

Shen J, Reis J, Morrison DC, Papasian C, Sreekumar R, Kolbert C, Qureshi AA, Vogel SN and Qureshi N: Key Inflammatory signapng pathways are regulated by the proteasome. Shock 2006, 25:472-484.

Reis J, Guan X-Q, Kisselev AF, Papasian CJ, Qureshi AA, Morrison DC, Van Way C III, Vogel SN, and Qureshi N. LPS-induced formation of immunoproteasomes: TNF-α and nitric oxide production are regulated by altered composition of proteasome-active sites. Cell Biochemistry and Biophysics (in press 2010).

Reis J, Hassan F, Guan X-Q, Shen J, Monaco JJ, Papasian CJ, Qureshi AA, Van Way C III, Vogel SN, Morrison DC, and Qureshi N. LMP Subunits of the proteasomes regulate the TRIF/TRAM pathway. Cell Biochemistry and Biophysics (in press 2010).


Photo of Steve Simon, Ph.D.
Steve Simon, Ph.D.
Research Professor Department of Biomedical & Health Informatics
  • 1982 -University of Iowa
  • Research interests: Accrual problems in clinical trials, information theory, monitoring adverse events in clinical trials, research ethics and risk adjustment models.
More Info

Research Summary

Most of my research is characterized as meta-research–research about the research process. One example is monitoring accrual patterns in prospective clinical trials. Another is mining the electronic health records to identify patients for clinical trials. A third example is comparing the initial IRB research application to what (if anything) gets published.


Photo of Kim Smolderen, Ph.D.
Kim Smolderen, Ph.D.
Assistant Professor — Implementation Science Department of Biomedical & Health Informatics
  • 2012, Post-Doctoral Fellowship in Outcomes Research PRT: American Heart Association, St. Luke’s Mid-America Heart Institute
  • 2009, PhD in Medical Psychology, Tilburg University, Tilburg Netherlands
More Info

Research Interest

An estimated 8 million individuals in the United States are affected by peripheral arterial disease (PAD), blockages of the leg arteries that can cause excruciating calf pain when walking. PAD can have a major impact on patients’ quality of life. It is also associated with high rates of heart attacks and premature death. While there are a number of treatments, there have been few previous studies that have prospectively examined treatment patterns for PAD or sought to systematically identify opportunities to improve care. Most importantly, there have been no rigorous studies examining the impact of the disease from patients’ perspectives-their symptoms, function, and quality of life-as a function of different patient characteristics and treatments. The PORTRAIT study (Phase II) will systematically document the treatments and health-status outcomes (symptoms, function, and quality of life) of 840 US patients from nine centers over the course of one year to address these gaps in knowledge. It will illuminate whether disparities in treatment or health-status outcomes exist as a function of a patient’s age, gender, race, or socioeconomic or psychological characteristics. As a direct deliverable, it will translate its findings-expected health status changes following PAD treatments over the course of one year-directly to patients through the development of education tools for patients with PAD who need to make a choice with regard to their treatment. As it is PCORI’s mission to assist patients, clinicians, purchasers, and policy makers in making informed health decisions with regard to diseases like PAD, PORTRAIT will substantially elevate the field and identify critical gaps in the way PAD is currently managed, including potential disparities in care, so that the quality of care can be improved. PORTRAIT will also be a critical first step in designing efficient, effective disease management programs for PAD in the future that are based on more personalized and healthcare system-oriented approaches to increase the use of evidence-based guidelines. Finally, as patients have been closely involved in the design of this study in Phase I and continue to be engaged as active advocates and experts on their disease throughout the current study, PORTRAIT will also empower patients and let them decide on what information and outcomes are most relevant for them while dealing with this burdensome condition of PAD.



Photo of David Voran, M.D.
David Voran, M.D.
Assistant Professor, University of Missouri-Kansas City Truman Medical CenterCommunity & Family Medicine
More Info

Research Interests

Medicare Wellness Visits: Missed opportunities for patient wellness, resident education and revenue. Implementation protocol for detection and management of postpartum hemorrhage. Direct patient participation in medical record management. Effectiveness of using a mobile app to identify sepsis compared to traditional SIRs criteria for inpatients. Does CMS transition of care codes with financial incentives and penalties decrease readmission rates at TMC?

Cardiology

More Info

Cardiology

Affiliated Faculty

Photo of Peter Koulen, Ph.D.
Peter Koulen, Ph.D.
Departments of Ophthalmology & Biomedical Sciences Work Phone: (816) 404-1824

Professor and Felix and Carmen Sabates Missouri Endowed Chair in Vision Research
Director of Basic Research, Vision Research Center
Department of Ophthalmology

Professor
Department of Biomedical Sciences

More info

Research Interest

Dr. Koulen is a Professor of Ophthalmology and Biomedical Sciences and the Felix and Carmen Sabates Missouri Endowed Chair in Vision Research at the UMKC School of Medicine. He trained at the Max-Planck-Institute for Brain Research, Yale University and the Marine Biological Laboratory. His research focuses on basic research on and therapy development for chronic diseases of the eye and brain. He is an internationally recognized expert in biophysics, biochemistry and physiology of nerve cells and his research has been funded continually since 2002 by national and international foundations and agencies including the NIH’s National Eye Institute, National Institute on Aging, National Cancer Institute, National Center for Research Resources, National Institute of Diabetes and Digestive and Kidney Diseases, and the U.S. DOD among others. As principal or co-investigator for over $20 million in extramural grant funding for research studies, Dr. Koulen’s research program has fundamental relevance to basic science, translational research and therapy development as evidenced by over 120 peer-reviewed publications in scientific journals, and 10 book chapters. Dr. Koulen has over 25 years of experience in the fields of neuroscience and eye research, drug development, translational research, biological sciences, biostatistics, and routinely interprets complex data sets with distinct public health significance. Dr. Koulen serves as reviewer for more than 50 professional scientific journals, serves on over 15 editorial boards and is editor in chief of two scientific journals. He is a review panel member for several national and international funding agencies including the National Science Foundation, the National Institutes of Health, the U.S. Department of Defense and other national and international government agencies and research foundations. The University of Missouri – Kansas City Board of Trustees recognized Dr. Koulen with the N.T. Veatch Award for Distinguished Research and Creativity. Through this Faculty Award, UMKC and the UMKC Trustees are recognizing the very best faculties, who have distinguished themselves through scholarship and creativity.

Vision research

Degeneration or acute damage of nerve cells in the retina is a major cause of visual loss and blindness in the United States and worldwide. As diseases such as glaucoma, macular degeneration and diabetic retinopathy affect significant and increasing portions of the U.S. population, including minorities affected by disparities in health care delivery, determining causes, mechanisms of action and subsequently potential treatment strategies will contribute to improving health care, health and performance requiring visual tasks.

The Vision Research Center was founded as and is a well-established collaboration of several UMKC schools and Kansas City Medical Centers and thus offers an unprecedented interdisciplinary synergy with a unified goal: to better diagnose, prevent, and treat eye disease and vision disorders through translational research in order to make a difference in the lives of tens of millions of people worldwide. To this end, the center conducts federally and industry funded basic, translational and clinical research to develop new medical therapies and offers patient care in all subspecialties of ophthalmology. The center’s nationally recognized excellence in research, patient care and medical education contribute to UMKC’s strengths in the life sciences. Objectives of the Vision Research Center are to:

  • Provide a direct avenue for basic and translational research in eye and related diseases,
  • Transfer basic science findings seamlessly into practical use with patients through translational research,
  • Develop new therapy approaches urgently needed by physicians in the US and worldwide,
  • Provide educational excellence,
  • Ensure patients receive the most advanced medical treatments available,
  • Become a national center of excellence for eye research.
Publications:

My NCBI Collections


Photo of Kim Smolderen, Ph.D.
Kim Smolderen, Ph.D.
Assistant Professor — Implementation Science Department of Biomedical & Health Informatics
  • 2012, Post-Doctoral Fellowship in Outcomes Research PRT: American Heart Association, St. Luke’s Mid-America Heart Institute
  • 2009, PhD in Medical Psychology, Tilburg University, Tilburg Netherlands
More Info

Research Interest

An estimated 8 million individuals in the United States are affected by peripheral arterial disease (PAD), blockages of the leg arteries that can cause excruciating calf pain when walking. PAD can have a major impact on patients’ quality of life. It is also associated with high rates of heart attacks and premature death. While there are a number of treatments, there have been few previous studies that have prospectively examined treatment patterns for PAD or sought to systematically identify opportunities to improve care. Most importantly, there have been no rigorous studies examining the impact of the disease from patients’ perspectives-their symptoms, function, and quality of life-as a function of different patient characteristics and treatments. The PORTRAIT study (Phase II) will systematically document the treatments and health-status outcomes (symptoms, function, and quality of life) of 840 US patients from nine centers over the course of one year to address these gaps in knowledge. It will illuminate whether disparities in treatment or health-status outcomes exist as a function of a patient’s age, gender, race, or socioeconomic or psychological characteristics. As a direct deliverable, it will translate its findings-expected health status changes following PAD treatments over the course of one year-directly to patients through the development of education tools for patients with PAD who need to make a choice with regard to their treatment. As it is PCORI’s mission to assist patients, clinicians, purchasers, and policy makers in making informed health decisions with regard to diseases like PAD, PORTRAIT will substantially elevate the field and identify critical gaps in the way PAD is currently managed, including potential disparities in care, so that the quality of care can be improved. PORTRAIT will also be a critical first step in designing efficient, effective disease management programs for PAD in the future that are based on more personalized and healthcare system-oriented approaches to increase the use of evidence-based guidelines. Finally, as patients have been closely involved in the design of this study in Phase I and continue to be engaged as active advocates and experts on their disease throughout the current study, PORTRAIT will also empower patients and let them decide on what information and outcomes are most relevant for them while dealing with this burdensome condition of PAD.


Photo of Michael Wacker, Ph.D.
Michael Wacker, Ph.D.
Assistant Dean of Medical Student Research Associate Teaching Professor, Vice-chair Biomedical SciencePhysiology, Biomedical Sciences Work Phone: (816) 235-6069
  • University of Kansas – Ph.D. (2003)
  • Texas Christian University – B.S. (1997)
More info

Biography

Dr. Wacker joined the Department of Basic Medical Science in the School of Medicine in 2007. He currently teaches physiology in the Human Structure Function series taught to the medical school students, as well as physiology courses in the Anesthesiologist Assistant program and the Physician Assistant program. Dr. Wacker is a member of the Muscle Biology Group at UMKC with expertise in cardiac muscle physiology. The interests in his laboratory focus on agents that alter cardiac muscle function and calcium homeostasis in cardiac myocytes. Acutely, changes in calcium homeostasis can lead to arrhythmias and alteration of cardiac muscle contractility. More chronic alterations in calcium, however, can lead to remodeling of the heart as observed in cardiac hypertrophy and heart failure. Specifically, Dr. Wacker is interested in endocrine/paracrine agents which may directly alter calcium changes in cardiac myocytes via signaling mediated by membrane receptors. Recently, Dr. Wacker and the Muscle Biology Group have worked in collaboration with the UMKC Bone Biology Group on a NIH-funded project exploring mechanisms of bone-muscle crosstalk. Dr. Wacker’s laboratory has concentrated on a hormone, FGF23, released by bone cells that may play a role in directly altering cardiac function during chronic kidney disease. Additional interests in the laboratory focus on how thromboxane A2, intracellular phosphoinositide signaling, and fibrate drugs may directly alter cardiac muscle function.

Research Interests

My laboratory is interested in agents that alter cardiac muscle function and calcium homeostasis in cardiac myocytes. I am specifically interested in endocrine/paracrine agents which may directly alter cardiac function. One main area of focus currently in the lab is on hormones/toxins (e.g. FGF23) that are elevated during chronic kidney disease that may cause heart disease. Typical experiments in the lab center around measuring cardiac contractility/ function, Langendorf perfusion of isolated hearts, calcium imaging of cardiac myocytes, cardiac gene/protein changes, exploring cardiac myocyte signal transduction mechanisms like IP3 signaling, and blood vessel function.

 

Recent Publications

Gallagher PM, Touchberry CD, Teson K, McCabe E, Tehel M, Wacker MJ. Effects of an acute bout of resistance exercise on fiber-type specific GLUT4 and IGF-1R expression. Applied Physiology, Nutrition, and Metabolism. 38 (5): 581-586, 2013. PMID: 23668768

Touchberry CD, Green TM, Tchikrizov V, Mannix JE, Mao TF, Carney BW, Girgis M, Vincent RJ, Wetmore LA, Dawn B, Bonewald L, Stubbs JR, Wacker MJ. FGF23 is a novel regulator of intracellular calcium and cardiac contractility in addition to cardiac hypertrophy. American Journal of Physiology: Endocrinology and Metabolism. 304 (8): E863-873. 2013. PMID: 23443925

Bonewald LF, Wacker MJ. FGF23 Production by Osteocytes. Pediatric Nephrology. 28 (4): 563-568. 2013. PMID: 22983423

Silswal N, Parelkar NK, Wacker MJ, Badr M, Andresen J.   PPARa-Independent Arterial Smooth Muscle Relaxant Effects of PPARa Agonists. PPAR Research. 302495. 2012. PMID: 23008696

Wacker MJ, Tevis O, Hanke J, Howard T, Gilbert W, Orr JA. Characterization of thromboxane A2 receptor and TRPV1 mRNA in cultured sensory neurons. Neuroscience Letters. 515(1):12-7. 2012. PMID: 22425716

Silswal N, Parelkar N, Wacker MJ, Brotto M, Andresen J. Phosphatidylinositol 3,5-bisphosphate increases intracellular free calcium in arterial smooth muscle cells and elicits vasocontraction. American Journal of Physiology: Heart and Circulatory Physiology. 300 (6): H2016-26. 2011. PMID: 21421826

Touchberry CD, Elmore CJ, Nguyen TM, Andresen JJ, Zhao X, Orange M, Weisleder N, Brotto M, Claycomb WC, Wacker MJ. Store-Operated Calcium Entry is Present in HL-1 Cardiomyocytes and Contributes to Resting Calcium. Biochemical and Biophysical Research Communications. 416 (1-2): 45-50. 2011. PMID: 22079292

Touchberry CD, Bales IK, Stone JK, Rohrberg TJ, Parelkar NK, Nguyen T, Fuentes O, Liu X, Qu CK, Andresen JJ, Valdivia HH, Brotto M, Wacker MJ. Phosphatidylinositol 3,5-Bisphosphate (PI(3,5)P2) Potentiates Cardiac Contractility Via Activation of the Ryanodine Receptor. Journal of Biological Chemistry. 285 (51): 40312-21. 2010. PMID: 20947503


Photo of John Qiang Wang, M.D., Ph.D.
John Qiang Wang, M.D., Ph.D.
Professor Departments of Anesthesiology & Biomedical Sciences Work M3-225 Work Phone: (816) 235-1907

Westport Anesthesia / Missouri Endowed Chair for Research

  • M.D. Degree: Tongji Medical University, Wuhan, China
  • MS Degree: Tongi Medical University, Wuhan, China
  • Ph.D, Degree: Shanghai Medical University, Shanghai China
  • Fellowship: Beijing Medical University, Beijing China
  • Fellowship: Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee
More info

Biography

John Q. Wang is a Westport Anesthesia/Missouri Endowed Chair in the Department of Anesthesiology and a Professor in the Departments of Anesthesiology and Basic Medical Science at UMKC School of Medicine since 2004. He earned his medical degree in Tongji Medical University in 1982 and his Ph.D. in Shanghai Medical University in 1988. Dr. Wang’s research primarily focuses on drug abuse and addiction. He currently leads a research team supported by NIH grants to conduct animal experiments from molecule to behavior and from in vitro to in vivo. In addition, Dr. Wang is interested in elucidating molecular mechanisms for anesthesia induction.

 

Grants:

NIH R01, DA10355, PI: Qiang Wang, Metabotropic glutamate regulation of amphetamine action, $1,698,750.00, 2013-2018.

NIH R01, MH61469, PI: Qiang Wang, Molecular regulation of metabotropic glutamate receptors in striatal neurons, $1,887,500.00, 2015-2020.

 

Selected Publications

Yang JH, Mao LM, Choe ES, Wang JQ (2017) Synaptic ERK2 phosphorylates and regulates metabotropic glutamate receptor 1 in vitro and in neurons. Mol Neurobiol in press. PMC5410195.

Xue B, Chen EC, He N, Jin DZ, Mao LM, Wang JQ (2017) Integrated regulation of AMPA glutamate receptor phosphorylation in the striatum by dopamine and acetylcholine. Neuropharmacology 112:57-65. PMC5055431.

Mao LM, Wang JQ (2017) Antagonism of dopamine D2 receptors alters phosphorylation of Fyn in the rat medial prefrontal cortex. J Mol Neurosci 61:524-530. PMC5360503.

Mao LM, Wang HH, Wang JQ (2017) Antagonism of muscarinic acetylcholine receptors alters synaptic ERK phosphorylation in the rat forebrain. Neurochem Res42:1202-1210. PMC5405859.

Mao LM, Geosling R, Penman B, Wang JQ (2017) Local substrates of non-receptor tyrosine kinases at synaptic sites in neurons. Acta Physiologica Sinica in press.

 

Presentations:

Faris HJ, He N, Wang JQ. Regulation of Src family kinases in the rat striatum by muscarinic acetylcholine receptors. Great Plains Honors Council Conference, Beaumont, TX, March 31-April 2, 2017.

Faris HJ, Mao LM, Wang JQ. Muscarinic acetylcholine receptors inhibit Src family kinase phosphorylation in the rat striatum. Health Sciences Student Research Summit. University of Missouri Kansas City, Kansas City, MO, April 26, 2017.

 

 

Internal Medicine-Adult, Oncology, Pathology

Pathology

More Information
Affiliated Faculty


Photo of Richard Butin, M.D.
Richard Butin, M.D.
Associate Professor – UMKC Truman Medical Center Hospital HillDepartment of Internal Medicine
  • Specialty: Internal Medicine
  • Bachelor of Arts: University of Kansas
  • Medical School: University of Kansas
  • Internal Medicine Residency: Cleveland Clinic Foundation and Hospital

Photo of Lawrence Dall, M.D.
Lawrence Dall, M.D.
Assistant Dean of Medical Student Research Clinical Professor of Medicine & Infectious DiseasesInternal Medicine
  • Medical School: Medical College of Wisconsin
  • Residency: Rutger Medical School
  • Fellowship: Hospitalist Leaders – University of California-San Francisco, Infectious Diseases – University of California-San Francisco
More Info

Quality Improvement Patient Safety

Glycocalyx


Photo of Mingui Fu, Ph.D.
Mingui Fu, Ph.D.
Associate Professor Immunology, Shock/Trauma Research CenterBiomedical Sciences Work MG-101A Work Phone: (816) 235-2193
  • M.S.:   Xian Medical University, China, 1994
  • Ph.D.:   Peking University Health Science Center, China, 2000
  • Postdoctoral Fellow: Morehouse School of Medicine, Atlanta, 2003 and UT Southwestern Medical Center, Dallas, 2006
More info
Research Interests:

Study the post-transcriptional regulatory mechanisms of inflammation and their contribution to human inflammatory diseases such as sepsis and vascular inflammatory diseases. Currently we are focus on a CCCH-zinc finger protein family including MCPIP1;

Post-translational regulation of vascular inflammation. Currently, we are focus on a newly identified E3 ligase. The techniques include: genetic animal studies, histology, immune staining, cell biology, molecular biology, biochemistry and human primary cells or sample analysis

Topics of Interest:
  • Regulatory mechanisms of septic shock
  • Signal transduction in macrophage activation
  • RNA metabolism in immune regulation
  • Negative regulation of Toll-like receptor signaling
  • Molecular signaling of vascular endothelial inflammation, injury and repair
  • Novel therapeutic targets for human inflammatory diseases including atherosclerosis, sepsis and viral infection
Recent Projects:
  1. The Roles of CCCH-Zinc Finger Proteins in the Regulation of Inflammation.
         Nearly 60 CCCH-zinc finger proteins have been identified in humans and mice. These proteins are involved in the regulation of multiple steps of RNA metabolism, including mRNA splicing, polyadenylation, transportation, translation, and decay. Several CCCH-zinc finger proteins, such as tristetraprolin, Roquin and MCPIP1, are crucial for many aspects of immune responses via targeting mRNA degradation and other mechanisms. Others are involved in the regulation of cell differentiation and cancer cell growth. In the past ten years, we have been working on a novel CCCH-zinc finger containing protein, MCPIP1, in the regulation of both innate and adaptive immunity. Using transgenic and knockout mouse models, we are studying the physiological role and mechanisms of MCPIP1 in inflammatory response and immunity and the involvement of MCPIP1 in septic shock, atherosclerosis and autoimmune diseases.
  2. Novel Molecular Regulators in Vascular Endothelial Inflammation, Injury and Repair.
         Vascular endothelium is a multifunctional and critical interface between blood stream and vascular wall. Meanwhile, vascular endothelium is also the largest endocrine, paracrine and metabolic organ. Recent studies suggest that there is endothelial dysfunction at the early stage of cardiovascular diseases and stroke caused by atherosclerosis, hypertension and diabetes. In addition, the initial event in bacterial and viral infection-caused multi-organ injury is vascular endothelial damage and dysfunction. So that vascular endothelial inflammation and dysfunction is a common pathological step and basis for cardiovascular diseases and stroke and acute organ injury. Improving the function of vascular endothelium and repairing the damaged vascular endothelium would be a critical step for treatment of cardiovascular diseases and stroke and acute organ injury. Using expression profiling and bioinformatics, we recently identified an adipocyte-enriched protein, adiporedoxin, as a negative regulator of endothelial activation (Sci Rep, 2016). In addition, we have identified a TRIM protein as a novel determinant of vascular endothelial inflammation via targeting VCAM-1 degradation. Currently, we are studying the roles and mechanisms of these proteins in vascular inflammation, atherosclerosis, sepsis and cerebral small vascular disease.
Selected Publications:
  1. Liang J, Wang J, Azfer A, Song W, Tromp G, Kolattukudy PE, Fu M#. A novel CCCH-Zinc finger protein family regulates proinflammatory activation of macrophages. J Biol Chem. 2008, 283:6337-6346.
  2. Liang J, Lei T, Song Y, Yanes N and Fu M#. RNA-destabilizing factor Tristetraprolin negatively regulates NF-κB signaling. J Biol Chem. 2009, 284: 29383-29390.
  3. Liang J, Saad Y, Lei T, Wang J, Qi D, Yang Q, Kolattukudy PE and Fu M#. MCP-induced protein 1 deubiquitinating TRAFs and negatively regulate JNK and NF-κB signaling. J Exp Med, 2010, 207:2959-73.
  4. Qi D, Huang S, Miao R, She ZG, Quinn T, Chang Y, Liu J, Fan D, Chen YE, Fu M#. Monocyte chemotactic protein-induced protein 1 (MCPIP1) suppresses stress granule formation and determines apoptosis under stress. J Biol Chem. 2011, 286(48):41692-700.
  5. Zhang Y, Breevoort SR, Angdisen J, Fu M, Schmidt DR, Holmstrom AR, Kliewer SA, Mangelsdorf DJ, Schulman IG. Liver LXRα expression is crucial for whole body cholesterol homeostasis and reverse cholesterol transport in mice. J Clin Invest, 2012, 122(5):1688-99.
  6. Zhang J, Zhang Y, Sun T, Chandalia M, Abate N, Fan D, Xin HB, Chen YE# and Fu M#. Dietary obesity induced Egr-1 in adipocytes facilitates energy storage via suppression of FOXC2. Sci Rep. 2013, 3:1476.
  7. Niu J, Shi Y, Xue J, Xu M, Miao R, Huang S, Chen ZJ, Fu M, Wu Z-H. DNA damage-induced MCPIP1 negatively regulates NF-κB activation by facilitating USP10-dependent disassembly of linear polyubiquitin chain. EMBO J, 2013, 32:3206-3219.
  8. Liu S, Qiu C, Miao R, Zhou J, Fu W, Zhu L, Zhang L, Xu J, Fan D, Li K, Fu M#, Wang T#. MCPIP1 restricts HIV infection and is rapidly degraded in activated CD4+ T cells. Proc Natl Acad Sci U S A., 2013, 110(47):19083-8.
  9. Yao H, Ma R, Yang L, Hu G, Chen X, Duan M, Kook Y, Niu F, Liao K, Fu M, Hu G, Kolattukudy P, Buch S. MiR-9 promotes microglial activation by targeting MCPIP1. Nat Commun. 2014. 5:4386.
  10. Jeltsch KM, Hu D, Brenner S, Zöller J, Heinz GA, Nagel D, Vogel KU, Rehage N, Warth SC, Edelmann SL, Gloury R, Martin N, Lohs C, Lech M, Stehklein JE, Geerlof A, Kremmer E, Weber A, Anders HJ, Schmitz I, Schmidt-Supprian M, Fu M, Holtmann H, Krappmann D, Ruland J, Kallies A, Heikenwalder M & Heissmeyer V. Cleavage of roquin and regnase-1 by the paracaspase MALT1 releases their cooperatively repressed targets to promote TH17 differentiation. Nat Immunol. 2014, 15(11):1079-1089.
  11. Huang S, Liu S, Fu JJ, Tony Wang T, Yao X, Kumar A, Liu G, Fu M#. Monocyte Chemotactic Protein-induced Protein 1 and 4 Form a Complex but Act Independently in Regulation of Interleukin-6 mRNA Degradation. J Biol Chem. 2015 Aug 21;290(34):20782-92.
  12. He H, Guo F, Li Y, Saaoud F, Kimmis BD, Sandhu J, Fan M, Maulik D, Lessner S, Fan D, Jiang ZS#, and Fu M#. Adiporedoxin suppresses endothelial activation via inhibiting MAPK and NF-κB signaling. Sci Rep. 2016 (in press).
  13. Jiang MX, Hong X, Liao BB, Shi SZ, Lai XF, Zheng HY, Xie L, Wang Y, Wang XL, Xin HB, Fu M#, and Deng KY#. Expression profiling identifies a novel group of TRIM proteins involving in the proinflammatory activation of macrophages. Sci Rep. 2016 (in press).


Photo of Mark Hoffman, Ph.D.
Mark Hoffman, Ph.D.
Department of Biomedical & Health Informatics

 

  • Research Associate Professor – Biomedical & Health Informatics
  • ResearchAssociate Professor – Pediatrics
  • Children’s Mercy Hospital – Director Translational Bioinformatics
More info

Biography

Dr. Mark Hoffman received his Ph.D. from the University of Wisconsin – Madison and performed post-doctoral research at the National Animal Disease Center in Ames, Iowa. Before joining UMKC, he spent 16 years leading genomics, public health and research initiatives at Cerner Corporation, where he was a Vice President. In addition to his peer-reviewed publications, Mark is an inventor on 16 issued patents.

Research Interests

CDC funded use of laboratory and medical data warehouses to support quality improvement.

Pharmacogenomic knowledge representation and decision support.

Influence of patient context on health, what I refer to as the ‘Envirome’.

View CV


Photo of Jared Keeler, M.D.
Jared Keeler, M.D.
  • Specialty: Internal Medicine
  • Medical School: University of Missouri-Kansas City
  • Internal Medicine Residency: University of Missouri-Kansas City

Photo of Peter Koulen, Ph.D.
Peter Koulen, Ph.D.
Departments of Ophthalmology & Biomedical Sciences Work Phone: (816) 404-1824

Professor and Felix and Carmen Sabates Missouri Endowed Chair in Vision Research
Director of Basic Research, Vision Research Center
Department of Ophthalmology

Professor
Department of Biomedical Sciences

More info

Research Interest

Dr. Koulen is a Professor of Ophthalmology and Biomedical Sciences and the Felix and Carmen Sabates Missouri Endowed Chair in Vision Research at the UMKC School of Medicine. He trained at the Max-Planck-Institute for Brain Research, Yale University and the Marine Biological Laboratory. His research focuses on basic research on and therapy development for chronic diseases of the eye and brain. He is an internationally recognized expert in biophysics, biochemistry and physiology of nerve cells and his research has been funded continually since 2002 by national and international foundations and agencies including the NIH’s National Eye Institute, National Institute on Aging, National Cancer Institute, National Center for Research Resources, National Institute of Diabetes and Digestive and Kidney Diseases, and the U.S. DOD among others. As principal or co-investigator for over $20 million in extramural grant funding for research studies, Dr. Koulen’s research program has fundamental relevance to basic science, translational research and therapy development as evidenced by over 120 peer-reviewed publications in scientific journals, and 10 book chapters. Dr. Koulen has over 25 years of experience in the fields of neuroscience and eye research, drug development, translational research, biological sciences, biostatistics, and routinely interprets complex data sets with distinct public health significance. Dr. Koulen serves as reviewer for more than 50 professional scientific journals, serves on over 15 editorial boards and is editor in chief of two scientific journals. He is a review panel member for several national and international funding agencies including the National Science Foundation, the National Institutes of Health, the U.S. Department of Defense and other national and international government agencies and research foundations. The University of Missouri – Kansas City Board of Trustees recognized Dr. Koulen with the N.T. Veatch Award for Distinguished Research and Creativity. Through this Faculty Award, UMKC and the UMKC Trustees are recognizing the very best faculties, who have distinguished themselves through scholarship and creativity.

Vision research

Degeneration or acute damage of nerve cells in the retina is a major cause of visual loss and blindness in the United States and worldwide. As diseases such as glaucoma, macular degeneration and diabetic retinopathy affect significant and increasing portions of the U.S. population, including minorities affected by disparities in health care delivery, determining causes, mechanisms of action and subsequently potential treatment strategies will contribute to improving health care, health and performance requiring visual tasks.

The Vision Research Center was founded as and is a well-established collaboration of several UMKC schools and Kansas City Medical Centers and thus offers an unprecedented interdisciplinary synergy with a unified goal: to better diagnose, prevent, and treat eye disease and vision disorders through translational research in order to make a difference in the lives of tens of millions of people worldwide. To this end, the center conducts federally and industry funded basic, translational and clinical research to develop new medical therapies and offers patient care in all subspecialties of ophthalmology. The center’s nationally recognized excellence in research, patient care and medical education contribute to UMKC’s strengths in the life sciences. Objectives of the Vision Research Center are to:

  • Provide a direct avenue for basic and translational research in eye and related diseases,
  • Transfer basic science findings seamlessly into practical use with patients through translational research,
  • Develop new therapy approaches urgently needed by physicians in the US and worldwide,
  • Provide educational excellence,
  • Ensure patients receive the most advanced medical treatments available,
  • Become a national center of excellence for eye research.
Publications:

My NCBI Collections



Photo of Agostino Molteni, M.D., Ph.D., F.A.C.C.B.
Agostino Molteni, M.D., Ph.D., F.A.C.C.B.
Director of Student Research UMKC School of Medicine
  • Professor of Pathology & Pharmacology – UMKC School of Medicine
  • Professor Emeritus of Pathology – Northwestern University
More info

Research Interests

Dr. Molteni’s main research interest is the study of development of interstitial pulmonary fibrosis (IPF) in several models of experimental lung injury: exposure to radiation and hypoxia, administration of bleomycin and fat embolism syndrome. Also studied is the role played by the renin angiotensin system in the development of fibrosis and the antifibrotic protection of angiotensin converting inhibitors or angiotensin II receptor blockers.

His projects are conducted in cooperation with Dr. Betty Herndon (UMKC SOM); Dr. T. McIff, Dept. of Orthopedic Surgery and Dr. A. Poisner, Dept. of Pharmacology, University of Kansas Medical Center, Dr. B. Uhal, Dept. of Physiology, Michigan State University, Dr. R. Baybutt, Dept. of Health Sciences, Wheaton College, Wheaton, IL., Dr. G Van Den Heuvel, Dept. of Physiology, Eastern Michigan University, Kalamazoo, MI.

Research Career Development Award, National Institutes of Health, 1972
Albert E. Lasker Award, 1980, to NHLBI sharing as principal investigator, Central Laboratory Hypertension Detection and Follow-up Program
Meritorious Service Award, Chicago Heart Association,1982
Clinical Chemists Recognition Award, 1983

Recent research includes the evaluation of exenatide in a rodent model of non-alcoholic liver steatosis, and in particular, the drug’s effect on the pancreas and the thyroid of these animals. This study was performed in cooperation with Dr. Herndon, Dr. Laura Alba, and others of the Dept. of Medicine, in the UMKC SOM. An additional study is the evaluation of pulmonary and cardiac damage in a model of Cux-1 mice expressing the cyclin kinase inhibitors P21 and P27 (Drs Baybutt and Van Den Heuvel).

Selected Publications

Has published more than 200 articles and book chapters and more than 370 presentations at national and international scientific meetings.

Curcumin Effects on Hepatic Steatosis and Histopathology in an Obese Mouse Model. British Journal of Medicine and Medical Research: 5(8): 1017-1023, 2015. Article no BJMMP.2015.112

Fat Embolism sensitizes rats to a “second hit” with LPS: an animal model of Pulmonary Fibrosis: Journal of Trauma and Acute Surgical Care; 783:552-557, 2015

Fat Embolism Syndrome following caesarean section in an obese patient and it’s similarity to an animal model of the same syndrome: a case report. Case reports in Clinical Pathology: Published online 3-3-2015, D01110.5430/crcp.vnp

NF-KB controls Resistance of Human Salivary Gland (HSG) Cells to apoptosis in an in vitro model of Sjögren syndrome. Open Journal of Rheumatology and Auto immune Diseases (OJRA): Vol 4 #3; ID: 2040 128, 2014

Mitigating effect of Captopril and Losartan on Lung Histopathology in a rat model of Fat Embolism. The Journal of Trauma 70 (5):1186-1191; 2011

Biochemical and Histological Effects of Exendin 4 (exenatide) in the rat pancreas. Diabetologia53(1):153-159; 2010

“Persistent and progressive fibrotic changes in a model of fat embolism.” Journal of Trauma 72 (h) 992-998, 2012

“Dietary flaxseed oil protects against bleomycin-induced pulmonary fibrosis in rats.” Pulmonary Medicine, published on line, June 2012 10457031 doi 0.1155/2012/457031

“Urease and Helicobacter spp. Antigens in Pulmonary Granuloma” Journal of Comparative Pathology(2012) http://dx.doi.org/10.1016/j.jcpa.2012.06.011

“Effect of exendin (exenatide) on the thyroid and parathyroid gland in a rat model.” Eur. J., of Pharmacology 2012 http://dx.doi.org/10.1016/j.ejphar.2012.07.024 



Photo of Carol Stanford, M.D.
Carol Stanford, M.D.
  • Specialty: Internal Medicine
  • Bachelor of Arts: University of Missouri-Kansas City
  • Medical School: University of Missouri-Kansas City
  • Internal Medicine Residency: University of Missouri-Kansas City
More Info

Research Interests

Dermatology case report, derm research project, book chapters and articles reviewing topics in derm, internal medicine, women’s health issues, domestic violence and intimate partner violence, physician burnout, ethics, humanities, reflective writing, creative video projects, empathy and humanism.


Photo of Gary Salzman, M.D.
Gary Salzman, M.D.
Professor of Medicine
  • Specialty: Pulmonary
  • Bachelor of Arts: University of Missouri-Kansas City
  • Medical School: University of Missouri-Kansas City
  • Internal Medicine Residency: Wake Forest University
  • Pulmonary Fellowship: University of Missouri-Kansas City
More info
Research Interests

In 1999 UMKC School of Medicine led by Gary A. Salzman MD, FCCP in partnership with Truman Medical Center and Children’s Mercy Hospital established the UMKC Asthma Clinical Research Center (ACRC) funded by a $500,000 grant over five years from the American Lung Association (ALA). In 2004 UMKC was awarded increased funding from the American Lung Association of $750,000 over 5 years.  Recently funding was extended for another 3 years until 2012.  The American Lung Association- Asthma Clinical Research Centers (ALA-ACRC) has successfully completed five clinical trials with several additional trials under way or in preparation. Currently there are 17 clinical centers and a data coordinating center at Johns Hopkins University.

Why did the ALA fund this large network? Health care providers caring for patients with asthma need answers quickly to provide the best care for their patients. Clinical studies performed at one center or even three or four centers may take up to five years to enroll enough subjects to answer such important questions.

The ALA recognized that 17 clinical centers will be able to enroll a large number of subjects in a relatively short period of time so the studies’ results can be published and health care providers can have the answers they need to provide the best evidence-based care to their patients with asthma.

Another advantage of a large network of clinical centers is the ability to enroll subjects from diverse populations. The populations represented in the ALA-ACRC studies include the same type of patients encountered by health care providers across the country.
Five practical and clinically important questions addressed by the ALA-ACRC are summarized below.

Vaccine safety

Is the influenza vaccine safe for patients with asthma?
The ALA-ACRC Network’s first endeavor was the Study of Inactivated Influenza Vaccine in Asthmatics (SIIVA). Influenza causes substantial morbidity in adults and children with asthma. However, the rate of vaccination for patients with asthma has been low partly due to fears of increased exacerbations from the vaccine.

The purpose of SIIVA was to evaluate the safety of the influenza vaccine in patients with asthma. The trial enrolled 2,032 participants in a three-month period between September and November 2000. Results showed rates of asthma exacerbations between vaccine and placebo injections were equivalent in a diverse population of adults and children with asthma, including severe asthma.  The results were published in the New England Journal of Medicine.

Health care providers should encourage patients with asthma to be immunized. Not only is the vaccine safe in this population, but vaccination also reduces the morbidity and mortality associated with influenza in patients with asthma.

Add-on controller medications

Which add-on controller medications work well for patients with uncontrolled asthma?
The ALA-ACRC Network’s second clinical trial was the Effectiveness of Low Dose Theophylline as Add-On Therapy in Treatment of Asthma (LODO).  Current guidelines recommend adding a controller medication to the treatment regimen of poorly controlled patients with asthma. Theophylline, a relatively inexpensive asthma medication, and anti-leukotriene agents such as montelukast, are convenient choices because both are once-a-day medications taken by mouth.
The comparative effectiveness of these two add-on treatments for poorly controlled asthma is unknown. LODO is the first clinical trial to directly compare theophylline to both active (montelukast) and placebo control.

The study enrolled 489 adolescents and adults with poorly controlled asthma over an 11-month period between 2001 and 2002.  The primary outcome was the rate of episodes of poor asthma control (EPACs). An EPAC is a composite measure of asthma control including measures of asthma control, need for medical care, and lung function.

Results showed neither low-dose theophylline nor montelukast decreased the rate of EPACs in patients with poorly controlled asthma as compared to the placebo group.  Both treatments did, however, improve lung function as measured by spirometry.

In a sub-group of patients not taking inhaled corticosteroids (ICS), monotherapy low-dose theophylline resulted in both statistically and clinically significant improvements in asthma control and symptoms. Montelukast was less effective in patients not on an ICS. As such, low-dose theophylline may provide an effective, safe and low-cost treatment alternative for patients with poorly controlled asthma who can’t or won’t use ICS because of side effects, preference, or cost.

Step-down therapy

Which step-down therapy options work well for patients with mild asthma?

Current guidelines for the treatment of patients with mild persistent asthma are to establish control of symptoms using inhaled corticosteroids and then “step-down” therapy to the minimum needed to maintain control. Although step-down therapy has been studied in patients with moderate to severe asthma, it hasn’t been systematically evaluated in patients with mild asthma. This was the purpose of the Leukotriene Modifier or Corticosteroids or Corticosteroid-Salmeterol (LOCCS) trial.

A large number of patients with asthma have a mild form of the disease. Encouraging patient adherence to asthma treatment regimens continues to present challenges. Providing patients with convenient, efficacious alternative treatments associated with fewer side effects could enhance adherence and reduce unnecessary medication exposure.

This clinical trial compared three alternative treatments for patients whose asthma was well controlled on low-dose inhaled corticosteroids. The treatment groups were fluticasone (100 mg twice a day), fluticasone plus salmeterol (100/50 mg once daily) or montelukast (10 mg or 5 mg daily for adults and children, respectively). The study randomized 500 children and adults; participant follow-up was completed in July 2005.

Results showed patients with asthma well controlled on twice-daily inhaled fluticasone can be stepped-down to once daily fluticasone/salmeterol without increased rates of treatment failure.

Stepping-down to montelukast resulted in an increase in treatment failures and decreased asthma control. Notably, however, there were a high number of symptom-free days for patients in all treatment groups, including 79 percent of days for patients taking montelukast over a four-month follow-up period.  Hence, oral montelukast isn’t as effective as either low-dose ICS (twice a day) or a low-dose ICS with salmeterol (once daily), but montelukast still provided good asthma control for most patients. The results were published in the New England Journal of Medicine.

Patient education

Are the effects of patient education real or not?

The Trial of Asthma Patient Education (TAPE) was designed to evaluate the effect of patient education on the treatment response to both placebo and montelukast. The National Heart Lung Blood Institute-funded trial completed enrollment in 2005, eight months ahead of schedule.

Patients randomized to montelukast or placebo was randomized again to receive either an enhanced presentation of the study treatment or a neutral presentation. The enhanced presentation was designed to increase expectancy of therapeutic benefit.

We compared effects of the enhanced presentation independently in the montelukast and placebo groups. This comparison addressed the question — does increasing expectancy improve outcomes equally in active treatment and placebo groups?

The usual care group was compared to the placebo group receiving the neutral presentation to estimate the placebo effect. Results showed the placebo and education effects were small for measures of lung function. However, there were effects on symptom indices such as Asthma Control Score.

Furthermore, “nocebo” effects were observed on side effects, such that more patients reported headache in the placebo group after receiving information about possible side effects than those on placebo who didn’t receive similar information. These results address the specific question about the best ways to evaluate new therapies for asthma and, more generally, how the use of placebo may affect the results of clinical trials.

The main results of the trial are currently being prepared for publication as well as results from several sub-studies evaluating adherence and education effects.

GERD & asthma

Can treatment with a proton pump inhibitor (PPI) of gastroesophogeal reflux disease improve asthma control?

GERD is common in patients with asthma, even in patients who have no symptoms of heartburn. It’s predicted that GERD may contribute to poor control of asthma but its unknown if empiric treatment of GERD in patients with poorly controlled asthma can improve control.

Two complementary clinical trials funded by the NHLBI in adults and children were  conducted by the ALA-ACRC. Both trials examine whether treatment with a PPI for GERD will improve asthma control in patients with poorly controlled asthma despite relatively high doses of inhaled steroids. Subjects undergo esophageal pH monitoring for the accurate diagnosis of GERD and have methacholine challenge testing to determine changes in bronchial reactivity. The adult study was completed in 2009 and demonstrated no improvement in asthma control with high dose proton pump inhibitor treatments. The results were published in the New England Journal of Medicine.  The pediatric study will be completed in 2011.

The ALA-ACRC has provided answers to important clinical questions for health care providers working in the trenches caring for asthma patients every day. Investigators on the ALA-ACRC steering committee are planning several future studies to improve the quality of life for adults and children living with asthma.  We recently have acquired funding from the NIH for two additional studies.  One study evaluates the administration of Soy supplements to uncontrolled asthmatics to determine if there is improved asthma control.  The other study evaluates the treatment of allergic rhinitis/sinusitis on asthma control.

The UMKC ACRC is one 17 centers nationwide undertaking a multi-center research approach to discovering improved methods to manage asthma with the long term goal to find a cure for asthma.  UMKC joins Johns Hopkins, Duke, Washington University in St. Louis, and many other prestigious universities in the largest industry independent research consortium to ever study asthma.

UMKC Lung Research Center

The Lung Research Center at UMKC was started by Dr. Salzman in 2005 to expand on the successes in clinical asthma research to include collaboration with UMKC basic science researchers.  Areas of planned studies include metabolic bone disease related to the use of systemic corticosteroids, discovery of novel mechanisms of disease in sarcoidosis, lung injury related to fat embolism from long bone fractures, and the genetic characteristics of asthma.

The collaboration of the clinical and basic science investigators with expertise in many aspects of lung disease will lead to significant discoveries that will be taken from bench to bedside to improve the treatment for many types of lung disease.  The addition of an endowed chair in lung research will serve as a catalyst for the expansion of research activities and funding.  Building on the strong foundation of existing funding and the talent of existing faculty the UMKC Lung Research Center will obtain international prominence in the next five years.

Peer Reviewed Publications

The American Lung Association Asthma clinical Research Centers (including GA Salzman). Clinical Trial of Low-dose Theophylline and Montelukast in Patients with Poorly Controlled Asthma. AJRCCM 2007. 175:235-242

The American Lung Association Asthma Clinical Research Centers (including GA Salzman). Randomized Comparison of Strategies for Reducing Treatment in Mild Persistent Asthma. N Eng J Med 2007; 356:2027-2039

Salzman GA. Smoking Ruins, The Prevention of Lung Disease. Missouri Medicine 2007; 104 (3): 208-209.

Khan ZU, Salzman GA. Management of Sepsis: The Surviving Sepsis Guidelines for Early Therapy. Hospital Physician 2007; 55:21-30.

The American Lung Association Asthma Clinical Research Center (including GA Salzman). Efficacy of Esomeprazole for Treatment of Poorly Controlled Asthma. N Engl J Med 2009;360:1487-99.

M Das, GA Salzman. Pulmonary Alveolar Proteinosis: An Overview for Internists and Hospital Physicians. Hospital Practice 2010;38(1):277-280.

Cox LS, Faseru B, Mayo MS, Krebill R, Snow TS, Bronars CA, Nollen NL, Choi WS, Okuyemi KS, Salzman GA, Benowitz NL, Tyndale RF, Ahluwalia JS. Design, baseline characteristics, and retention of African American light smokers into a randomized trial involving biological data. Trials 2011, 12:22

Jallu SS, Salzman GA. A Case-Based Approach to Noninvasive Positive Pressure Ventilation. Hospital Practice 2011; 39(3):168-175.

The American Lung Association Asthma Clinical Research Center (including GA Salzman). Lansoprazole for Children with Poorly Controlled Asthma. JAMA. 2012;307(4):373-381

Saettele TM, Mohr J. Evaluation and Management of Acute Kidney Injury in the Intensive Care Unit. Missouri Medicine 2012:109(5):379-383

Research Support

The Leukotriene Modifier Or Corticosteroids Trial (The LOCS Trial):

A Comparison of Continued Low-Dose Inhaled Corticosteroids versus Leukotriene Modifier for Asthmatic Patients Well Controlled with Low Dose Inhaled Corticosteroids, Principal investigator. Funding from GlaxoSmithKline $4,633,888 total funding over 5 years to Asthma Clinical Research Centers 2001-2006 One of 19 principal investigators.

The Trial of Asthma Patient Education, Funding from National Heart, Blood and Lung Institute $2,570,617 total funding over 4 years to Asthma Clinical Research Centers 2002-2006. One of 19 principal investigators

Study of Acid Reflux in Asthma, Funding from National Heart, Blood and Lung Institute $3,800,627 total funding over 5 years to Asthma Clinical Research Centers 2004-2009. One of 19 principal investigators

Study of Acid Reflux in Childhood Asthma, Funding from National Heart, Blood and Lung Institute $2,414,841 total funding over 5 years to Asthma Clinical Research Centers 2007-2012 One of 20 principal investigators

American Lung Association: Asthma Clinical Research Center: 2009-2012 for $300,000. Principal Investigator

Missouri Hospital Association Regional Health Partnership Grant for Asthma Education and Research Programs- $100,000; 2002-2006. Principal Investigator

Blue Cross and Blue Shield of Kansas City: $49,875. Developing a culturally tailored smoking cessation program for heavily addicted Chronic Obstructive Pulmonary Disease (COPD) patients; Principal Investigator 2007-2009

American Lung Association Asthma Clinical Research Centers (ACRC)
The Study of Soy Isoflavones in Asthma (SOYA) National Heart, Blood and Lung Institute: R01 HL0088367-01A2- total funding $1.5 million- one of 18 ACRC multi-center co-investigators 2010-2013

American Lung Association Asthma Clinical Research Centers (ACRC) Study of Asthma and Nasal Steroids (STAN) National Heart, Blood and Lung Institute: U01 HL00895101-01A2- total funding $2.1
One of 18 ACRC multi-center co-investigators 2010-2013

Geldmacher Pulmonary Fibrosis Research Center 2012-2017 $400,000 Principal Investigator


Photo of Lamont G. Weide, M.D., Ph.D.
Lamont G. Weide, M.D., Ph.D.
Professor Department of Internal Medicine
  • Specialty: Endocrinology and Metabolism
  • Medical School: University of Texas, San Antonio
  • Doctoral Degree: University of Texas, Dallas
  • Postdoctoral Training: University of Texas, San Antonio
  • Internal Medicine Residency: Indiana University Medical Center
  • Endocrinology and Metabolism Fellowship: Washington University, St. Louis
  • Research Interests: Diabetes, Thyroid Cancer

Photo of Mudassar Zia, M.D.
Mudassar Zia, M.D.
Core Faculty Assistant Professor of MedicineSection Chief, Division of General Internal Medicine, Geriatrics, and Hospital Medicine

Joined UMKC Faculty in 2010

  • Medical School: Ayub Medical College
  • Residency: Internal Medicine, Nassau University Medical Center
  • Fellowship: Geriatrics, Duke University Medical Center
  • Medical Interests: curriculum development, bedside teaching

More Info

Gastroparesis and its impact on chronic medical conditions.

Neurology/Neuroscience, Psychiatry

Neurology

More Information
Affiliated Faculty


Photo of Robert J. Batterson, M.D.
Robert J. Batterson, M.D.
Associate Professor, University of Missouri-Kansas City Children’s Mercy HospitalPediatrics
More Info

Research Interests

SPRITES: A project to identify if there are neuropsychological or developmental problems with long term use of sertraline.–Industry funded. National Mental Health Registry: use of ‘Big Data’ in understand outcomes for people treated for mental illness.–We would be a site if approved.


Photo of Nash N. Boutros, MBBCH
Nash N. Boutros, MBBCH
Department Chair and Professor Center for Behavioral MedicinePsychiatry
More Info

Research Interests

Coherence abnormalities in panic disorder; relationship to epilepsy. Coherence abnormality in psychogeneic non-epileptic seizures. EEG and MEG abnormalities in schizophrenia.


Prakash Chandra, M.D.
Assistant Professor Truman Medical Centers Behavioral HealthPsychiatry
  • Specialty: Child & Adolescent Psychiatry
More Info

Research Interests

Current project: looking at the behaviors during obstetric Ultrasound for correlation with mental health and obstetric outcomes

Future projects:

  • Collaboration with the KU MEG team on perinatal mental health.
  • Telemedicine


Photo of Fu-Sheng Chou, M.D., Ph.D.
Fu-Sheng Chou, M.D., Ph.D.
Assistant Professor, University of Missouri-Kansas City Children’s Mercy HospitalPediatrics
More Info

Research Interests

Epigenetic regulation of fetal brain development.


Photo of Xiang-Ping Chu, M.D., Ph.D.
Xiang-Ping Chu, M.D., Ph.D.
Associate Professor with Tenure Biomedical Sciences, Neuroscience Work M3-417 Work Phone: (816) 235-2248
  • Robert S. Dow Neurobiology Laboratories, Legacy Research Institute, Postdoctoral Fellowship (Neurobiology, 2004)
  • Fudan University Shanghai Medical College, Ph.D. (Physiology, 1999)
  • Fudan University Shanghai Medical College, MS (Physiology 1996)
  • Jiangsu University School of Medicine, MD (Clinical Medicine, 1989)
More info

Biography

Dr. Chu earned his medical degree from Jiangsu University School of Medicine in 1989, and his PhD degree from Fudan University Shanghai Medical College in 1999, both in the People’s Republic of China. He then came to America for postdoctoral training at the Legacy Research Institute in Portland, Oregon in 2000. He received a postdoctoral fellowship from the American Heart Association (AHA) in 2002 and subsequently received a beginning grant-in-aid in 2004 and scientist development grant in 2007, both from the AHA. While at the Legacy Research Institute, Dr. Chu was promoted from research associate to senior research associate, to assistant scientist. In 2008, he was recruited to the UMKC School of Medicine as a tenure-track Assistant Professor to establish an advanced, independent electrophysiology laboratory in a strategic expansion of neuroscience research program. In 2014, Dr. Chu was promoted to Associate Professor with tenure. His research focuses on the role of ion channels and membrane receptors in the pathogenesis of neurological disorders such as stroke and drug addiction. While at UMKC, his research has been supported by the National Institute of Health (NIH) and the AHA. Dr. Chu teaches medical neuroscience and physiology courses and is a member of UMKC’s doctoral faculty. He has published 3 book chapters and more than 50 peer-reviewed articles with an H-index of 18, and has served as a peer-reviewer for over 30 scientific journals. Dr. Chu currently serves on Editorial Boards for Advances in Neuroscience, International Journal of Physiology, Pathophysiology & Pharmacology (IJPPP), ISRN Physiology, and Scientific Reports. Dr. Chu also serves on grant study sections for the AHA, Medical Research Council of UK, Ataxia Foundation of UK, and the University of Missouri Research Board (UMRB).

Research Interest

One of my research interests is to understand the functional role of ion channels in ischemic brain injury. Brain ischemia induces various biochemical changes, which can activate various ion channels, including Acid-Sensing Ion Channels (ASICs). During hypoxia/ischemia, increased anerobic glycolysis due to the lack of blood and oxygen supply leads to lactic acid accumulation, causing a reduction in pH, and acidosis. For many years, acidosis has been known to play an important role in the pathology of neuronal injury. However, the cellular and molecular mechanisms underlying acidosis-induced injury remain elusive. Recently we have demonstrated that activation of newly described

ASICs contribute to neuronal injury, particularly those containing the ASIC1a subunit. My aim is to explore the potential mechanisms by which ASIC’s are involved in the pathogenesis of ischemic brain injury, particularly the extent to which they might be modulated/regulated by endogenous molecules (e.g. glucose and zinc). ASICs localize to synapses and proton as a neurotransmitter released from synaptic vesicles activates ASICs during neurotransmission. I am also interested in studying the functional role of ASICs in the brain and the interaction between ASICs and other ion channels/receptors (for example, glutamate receptors, dopamine receptors et al.,) during physiological or pathological conditions such as drug abuse. We want to determine whether ASICs play any roles in the pathogenesis of drug abuse or interact with other receptors in the brain in response to psychostimulants.

Mentoring Area

I am interested in mentoring students who have interests in neurological diseases such as drug abuse and ischemic brain injury using a combination of patch-clamp recording, fluorescence-imaging, gene transfection and knockdown, cell injury assay and behavior measurement techniques.

Recent Publications

*Chu XP, Grasing KA, Wang JQ. Acid-sensing ion channels contribute to neurotoxicity. Transl Stroke Res. 5(1):69-78, 2014. *Corresponding author.

Jing L, *Chu XP, *Zha XM. Three distinct motifs within the C-terminus of ASIC1a regulate its surface trafficking. Neuroscience. 247: 321-327, 2013. *Corresponding author.

Jiang Q, Wang CM, Fibuch EE, Wang JQ, *Chu XP. Differential regulation of locomotor activity to acute and chronic cocaine administration in acid-sensing ion channels 1a and 2 in adult mice. Neuroscience. 246C:170-178, 2013. *Corresponding author.

*Chu XP, Xiong ZG. Acid-sensing ion channels in pathological conditions. Adv Exp Med Biol. 961:419-31, 2013. *Corresponding author.

Jiang Q, Zha XM, *Chu XP. Inhibition of human acid-sensing ion channel 1b by zinc. Int J Physiol Pathophysiol Pharmacol4(2):84-93, 2012. *Corresponding author.

Wang JQ, Chu XP, Guo ML, Jin DZ, Xue B, Berry TJ, Fibuch EE, Mao LM. Modulation of ionotropic glutamate receptors and acid-sensing ion channels by nitric oxide. Front Physiol. 3:164, 2012.

*Chu XP, *Jing L,*Jiang YQ, Collier DM, Wang B, Jiang Q, Snyder PM and Zha XM. N-Glycosylation of ASIC1a regulates its trafficking and acidosis-induced spine remodeling. J Neurosci.  32(12):4080-4091, 2012. *These authors contributed equally.

*Chu XP, Xiong ZG. Physiological and pathological functions of acid-sensing ion channels in central nervous system. Curr Drug Targets. 13(2):263-271, 2012. *Corresponding author.

*Chu XP, Papasian CJ, Wang JQ and Xiong ZG. Modulation of Acid-Sensing Ion Channels: Molecular Mechanisms and Therapeutic Potential. Int J Physiol Pharmacol. 3(4):288-308, 2011. *Corresponding author.

Jing L, Jiang Q, Jiang YQ, Chu XP, and Zha XM. Interaction between the first transmembrane domain and the wrist of acid-sensing ion channel 1a is critical for its maturation and trafficking.  PLoS One, 6(10):e26909, 2011.

Jiang Q, Inoue K, Wu X, Papasian CJ, Wang JQ, Xiong ZG, *Chu XP. Cysteine 149 in the extracellular finger domain of ASIC1b subunit is critical for zinc-mediated inhibition. Neuroscience, 193: 89-99, 2011. *Corresponding author.

Duan B, Wang YZ, Yang T, Chu XP, Yu Y, Huang Y, Cao H, Hansen J, Simon RP, Zhu MX, Xiong ZG, Xu TL. Extracellular spermine exacerbates ischemic neuronal injury through sensitization of ASIC1a channels to extracellular acidosis. J Neurosci. 31: 2101-2112, 2011.

Van Dolah DK, Mao LM, Shaffer C, Guo ML, Fibuch EE, Chu XP, Buch S, Wang JQ. Reversible palmitoylation regulates surface stability of AMPA receptors in the nucleus accumbens in response to cocaine in vivo. Bio Psychiatry. 69: 1035-1042, 2011.

Lin J, Chu XP, Maysami S, Li M, Si H, Cottrell JE, Simon RP, Xiong ZG. Inhibition of acid-sensing ion channel currents by lidocaine in cultured mouse cortical neurons. Anesth Analg. 112:977-981, 2011.

*Chu XP, *Coombes E, *Jiang J, Inoue K, Seeds J, Branigan D, Simon RP, Xiong ZG. Pathophysiological relevant levels of hydrogen peroxide induces glutamate-independent neurodegeneration that involves activation of TRPM7 channels. Antioxid Redox Signal. 14: 1815-1827, 2011. *These authors contributed equally.

Suman A, Mehta B, Guo ML, Chu XP, Fibuch EE, Mao LM and Wang JQ. Alterations in acid-sensing ion channel expression in the rat forebrain following chronic amphetamine administration. Neurosci Res. 68: 1-8, 2010.

Jiang Q, Papasian CJ, Wang JQ, Xiong ZG and *Chu XP. Inhibitory regulation of acid-sensing ion channel 3 by zinc. Neuroscience. 169: 574-583, 2010. *Corresponding author.

*Chu XP, *Mao LM, *Wang W, Zhang GC, Liu XY, Yang YJ, Haines M, Papasian CJ, Fibuch EE, Buch S, Chen JG, Wang JQ. Stability of surface NMDA receptors controls synaptic and behavioral adaptations to amphetamine. Nat Neurosci. 12: 602-10, 2009. *These authors contributed equally.

Jiang Q, Li MH, Papasian CJ, Branigan D, Xiong ZG, Wang JQ, *Chu XP. Characterization of acid-sensing ion channels in medium spiny neurons of mouse striatum. Neuroscience. 162: 55-66, 2009. *Corresponding author.

Zhang GC, Mao LM, Wang JQ, *Chu XP. Upregulation of acid-sensing ion channel 1 protein expression by chronic administration of cocaine in the mouse striatum in vivo. Neurosci Lett. 459:119-22, 2009. *Corresponding author.

Jiang J, Li MH, Inoue K, Chu XP, Seeds J, and Xiong ZG. TRPM7-like current in human head and neck carcinoma cells: role in cell proliferation. Cancer Res.,67:10929-38, 2007.

Liu X, Chu XP, Mao L, Wang M, Lan H, Li MH, Zhang G, Parelkar NK, Haines M, Neve KA, Liu F, Xiong ZG, and Wang JQ. Modulation of D2R/NR2B interactions in response to cocaine. Neuron, 52, 897-909, 2006.

Chu XP, Close N, Saugstad JA, and Xiong ZG. ASIC1a-specific modulation of acid-sensing ion channels in mouse cortical neurons by redox reagents. J. Neurosci., 26:5329-5339, 2006.

Xiong ZG, *Chu XP, *Zhu XM, Minami M, Hey J, Wemmie JA, Price M, Welsh MJ, and Simon RP.  Neuroprotection in ischemia: blocking calcium-permeable acid-sensing ion channels. Cell. 118(6): 687-698, 2004. *These authors contributed equally.

Chu XP, Wemmie JA, Wang WZ, Zhu XM, Saugstad JA, Price MP, Simon RP, Xiong ZG.   Subunit-dependent High-Affinity Zinc Inhibition of Acid-Sensing Ion Channels. J. Neurosci., 24 (40): 8678-8689, 2004.


Photo of Keith Coffman, M.D.
Keith Coffman, M.D.
Associate Professor, UMKC School of Medicine Children’s Mercy HospitalDepartment of Neurology, Child Neurology
More info

Education
  • Medical School: Pennsylvania State University College of Medicine
  • Residency: Children’s Hospital of Pittsburgh – Neurodevelopmental Disabilities
  • Fellowship: University of Pittsburgh School of Medicine – Pediatric Scientist Development Program
Research Interests
  • Analysis of androgens in Tourette Syndrome. We hypothesize that patients with Tourette Syndrome have higher excretion of androgens compared to age matched controls. This may be part of the reason that Tourette is more common in young men, and typically worsens around the onset of puberty.
  • Repetitive transcranial magnetic stimulation (rTMS)to treat Tourette Syndrome. There is early data to indicate that rTMS may be effective for treating Tourette. We have partnered with an external colleague who has a novel, patented rTMS device that we will be trialing as a treatment for patients affected by Tourette.
  • Prospective, multicenter analysis of sleep disorders in medication naïve patients with Tourette Syndrome. We have some preliminary data that indicates that patients with Tourette may have higher rates of restless leg syndrome and other sleep disorders. We will use standardized sleep questionnaires, analysis of serum ferritin levels, and Yale Global Tic Severity scales to assess these patients.
  • Neuropsychological profiles of patients with Tourette Syndrome. Out neuropsychologist, Josh Hall, has accumulated years of data on patients with Tourette. There is precious little data on the neuropsychological deficits seen in Tourette. We plan to analyze the accumulated clinical data on our patient population and see if specific patterns of deficits are present in this patient population.
  • Behavioral patterns of patients with Tourette. One of our nurse practitioners, Laura Banning, plans to analyze patterns of maladaptive behavior in patients with Tourette using the Child Behavior Checklist (CBCL).

For additional information, please click here.

 



Photo of Lindsay Fazio, Ph.D.
Lindsay Fazio, Ph.D.
Assistant Professor, University of Missouri-Kansas City Truman Medical CenterCommunity & Family Medicine
More Info

Research Interests

Impact of BH integration into family medicine on chronic disease. Using strengths model to address burnout


Jessica A. Hellings, M.B.B.Ch.
Professor, University of Missouri-Kansas City Center for Behavioral MedicinePsychiatry
More Info

Research Interests

Psychopharmacology studies of old drugs in autism: Loxapine, amitriptyline, dextroamphetamine, BDNF Attachment in Developmental Disabilities ADHD in ASD/DD Psychological mindedness Gluten allergy, celiac disease and neuropsychiatric illness; gut-brain biology in neuropsychiatric illness.



Photo of Jared Keeler, M.D.
Jared Keeler, M.D.
  • Specialty: Internal Medicine
  • Medical School: University of Missouri-Kansas City
  • Internal Medicine Residency: University of Missouri-Kansas City

Photo of Peter Koulen, Ph.D.
Peter Koulen, Ph.D.
Departments of Ophthalmology & Biomedical Sciences Work Phone: (816) 404-1824

Professor and Felix and Carmen Sabates Missouri Endowed Chair in Vision Research
Director of Basic Research, Vision Research Center
Department of Ophthalmology

Professor
Department of Biomedical Sciences

More info

Research Interest

Dr. Koulen is a Professor of Ophthalmology and Biomedical Sciences and the Felix and Carmen Sabates Missouri Endowed Chair in Vision Research at the UMKC School of Medicine. He trained at the Max-Planck-Institute for Brain Research, Yale University and the Marine Biological Laboratory. His research focuses on basic research on and therapy development for chronic diseases of the eye and brain. He is an internationally recognized expert in biophysics, biochemistry and physiology of nerve cells and his research has been funded continually since 2002 by national and international foundations and agencies including the NIH’s National Eye Institute, National Institute on Aging, National Cancer Institute, National Center for Research Resources, National Institute of Diabetes and Digestive and Kidney Diseases, and the U.S. DOD among others. As principal or co-investigator for over $20 million in extramural grant funding for research studies, Dr. Koulen’s research program has fundamental relevance to basic science, translational research and therapy development as evidenced by over 120 peer-reviewed publications in scientific journals, and 10 book chapters. Dr. Koulen has over 25 years of experience in the fields of neuroscience and eye research, drug development, translational research, biological sciences, biostatistics, and routinely interprets complex data sets with distinct public health significance. Dr. Koulen serves as reviewer for more than 50 professional scientific journals, serves on over 15 editorial boards and is editor in chief of two scientific journals. He is a review panel member for several national and international funding agencies including the National Science Foundation, the National Institutes of Health, the U.S. Department of Defense and other national and international government agencies and research foundations. The University of Missouri – Kansas City Board of Trustees recognized Dr. Koulen with the N.T. Veatch Award for Distinguished Research and Creativity. Through this Faculty Award, UMKC and the UMKC Trustees are recognizing the very best faculties, who have distinguished themselves through scholarship and creativity.

Vision research

Degeneration or acute damage of nerve cells in the retina is a major cause of visual loss and blindness in the United States and worldwide. As diseases such as glaucoma, macular degeneration and diabetic retinopathy affect significant and increasing portions of the U.S. population, including minorities affected by disparities in health care delivery, determining causes, mechanisms of action and subsequently potential treatment strategies will contribute to improving health care, health and performance requiring visual tasks.

The Vision Research Center was founded as and is a well-established collaboration of several UMKC schools and Kansas City Medical Centers and thus offers an unprecedented interdisciplinary synergy with a unified goal: to better diagnose, prevent, and treat eye disease and vision disorders through translational research in order to make a difference in the lives of tens of millions of people worldwide. To this end, the center conducts federally and industry funded basic, translational and clinical research to develop new medical therapies and offers patient care in all subspecialties of ophthalmology. The center’s nationally recognized excellence in research, patient care and medical education contribute to UMKC’s strengths in the life sciences. Objectives of the Vision Research Center are to:

  • Provide a direct avenue for basic and translational research in eye and related diseases,
  • Transfer basic science findings seamlessly into practical use with patients through translational research,
  • Develop new therapy approaches urgently needed by physicians in the US and worldwide,
  • Provide educational excellence,
  • Ensure patients receive the most advanced medical treatments available,
  • Become a national center of excellence for eye research.
Publications:

My NCBI Collections


Matthew McLaughlin, M.D.
Assistant Professor Children’s Mercy Hospital
More Info

Research Interests

I am willing to tailor projects to meet the needs of students; however, they should be in my discipline of Pediatric or Adult Physical Medicine and Rehabilitation. Some unique areas of interest are: Cerebral palsy Clinical pharmacology Spasticity management Adaptive sports Disability populations Concussion Traumatic brain or spinal cord injury.


Photo of Cy B. Nadler, Ph.D.
Cy B. Nadler, Ph.D.
Assistant Professor, University of Missouri-Kansas City Children’s Mercy HospitalPediatrics
More Info

Research Interests

I lead multiple research projects in the areas of Autism Spectrum Disorders and Developmental Disabilities: One series of projects is focused on autism and developmental screening in primary care medical settings. We have an ongoing quality improvement initiate at Children’s Mercy, which has yielded a large health database. We have use this database for additional projects related to health disparities and health outcomes related to screening. I am interested in research related to parenting and autism/developmental disabilities, health care access, health & treatment outcomes, dissemination, and the education and training of healthcare professionals about developmental disabilities. Finally, I am the site PI for a large epidemiological study on autism and developmental disabilities funded by the Centers for Disease Control.


Photo of Paula Monaghan-Nichols, Ph.D.
Paula Monaghan-Nichols, Ph.D.
Associate Dean for Research, Chair and Professor Biomedical Sciences Biomedical Sciences Home M3-C02 Work Phone: (816) 235-6663
  • Trinity College, Dublin, Ireland, BA (Genetics)
  • Medical Research Council, Edinburgh, Scotland, Ph.D. (Genetic Engineering and Molecular Biology)
  • Medical Research Council, Human Genetics Unit, Edinburgh, Scotland, Post-Graduate (Molecular Genetics and Development)
More info

Research and Professional Experience

Postdoctoral Fellow/Research Associate, Molecular Biology of the Cell 1, German Cancer Research Centre, Heidelberg, Germany.

Assistant Professor, Department of Neurobiology, University of Pittsburgh School of Medicine, Pittsburgh, PA

 Associate Professor, Department of Neurobiology, University of Pittsburgh School of Medicine, Pittsburgh, PA

Research Interest

Molecular Genetic Analysis of the Developmental Basis of Neuropsychiatric Disorders

Research Summary

My laboratory focuses on understanding the molecular and developmental basis of emotional and cognitive behavior and psychiatric illness. The long-term goal of my research is to identify both intrinsic and environmental factors that specifically alter the development of areas in the brain that are essential for emotion and cognition.  My laboratory has identified a number of transcriptional repressors (Tlx, Sall1, Sall2, Sall3 and Sall4) that are expressed in the developing forebrain. This research has shown that these genes are express in stem and progenitor cells in the cerebral cortex, and are required to regulate the rate of stem/progenitor cell proliferation and neuronal differentiation.  Using both conditional and classical knockout experiments and in-utero electroporation studies in mice, my laboratory has shown that altering the levels of these proteins during development leads to emotional, behavioral and cognitive abnormalities in adult animals.  Our most recent studies focus on identifying the cellular and biochemical targets of glucocorticoid action on the developing brain in-utero. Synthetic glucocorticoids are administered to mothers at risk for pre-term labor, to stimulate lung maturation and to reduce the risk of intraventricular hemorrhage and necrotizing enterocolitis. Clinical follow up studies indicate that children exposed to steroid in-utero have cognitive abnormalities and an altered stress response. My laboratory is using a combination of molecular, cellular, proteomic, RNA-Seq. and genome wide DNase hypersensitive site mapping to identify the cellular targets of steroid action. These studies have shown that prenatal exposure to glucocorticoids leads to changes in neuronal number and density in the cerebral cortex at birth coupled to long-term alterations in neurite complexity in the prefrontal cortex and hippocampus in adolescents. These anatomical abnormalities are associated with changes in anxiety and depressive like behaviors in adults. Follow up studies include validating our identified targets in human brain and in umbilical cord blood cells.  These findings will for a framework for modifying current clinical dosing regiments in preterm labor to reduce the adverse consequences of premature exposure to corticosteroids in-utero.

Current Research Project(s)

This project examines the developmental basis of neurological abnormalities. Several approaches are used to investigate how environmental or genetic factors influence neural stem cell behavior and how perturbing these processes leads to anatomical and behavioral abnormalities. We are particularly interested in environmental factors that act in-utero such as steroid use, cannabinoids, hypothermia etc. Specific techniques include mouse transgenics, molecular and cellular biology, biochemistry, tissue culture, human umbilical cord blood cell, single nucleotide polymorphism, RNA seq and genetic databases.

Selected Publications

Research Resource: The Dexamethasone Transcriptome in Hypothalamic Embryonic Neural Stem Cells.Frahm KA, Peffer ME, Zhang JY, Luthra S, Chakka AB, Couger MB, Chandran UR, Monaghan AP, DeFranco DB. Mol Endocrinol. 2016 Jan;30(1):144-54.

Genome-wide transcript profiling reveals novel breast cancer-associated intronic sense RNAs.Kim SW, Fishilevich E, Arango-Argoty G, Lin Y, Liu G, Li Z, Monaghan AP, Nichols M, John B. PLoS One. 2015 Mar 23;10(3):e0120296..

Caveolin-1 regulates genomic action of the glucocorticoid receptor in neural stem cells.Peffer ME, Chandran UR, Luthra S, Volonte D, Galbiati F, Garabedian MJ, Monaghan AP, DeFranco DB. Mol Cell Biol. 2014 Jul;34(14):2611-23.

Wu P1, Teot L, Murdoch GH, Monaghan-Nichols P, McFadden K.  Neuropathology of 22q11 Deletion Syndrome in an Infant. Pediatr Dev Pathol. 2014 17(5):386-92.

An in-depth map of polyadenylation sites in cancer. Lin Y, Li Z, Ozsolak F, Kim SW, Arango-Argoty G, Liu TT, Tenenbaum SA, Bailey T, Monaghan AP, Milos PM, John B. Nucleic Acids Res. 2012 Sep 1;40(17):8460-71.

Sall1 regulates cortical neurogenesis and laminar fate specification in mice: implications for neural abnormalities in Townes-Brocks syndrome. Harrison SJ, Nishinakamura R, Jones KR, Monaghan AP. Dis Model Mech. 2012 May;5(3):351-65.

 Comprehensive polyadenylation site maps in yeast and human reveal pervasive alternative polyadenylation. Ozsolak F, Kapranov P, Foissac S, Kim SW, Fishilevich E, Monaghan AP, John B, Milos PM. Cell. 2010 Dec 10;143(6):1018-29. doi: 10.1016/j.cell.

New class of gene-termini-associated human RNAs suggests a novel RNA copying mechanism.Kapranov P, Ozsolak F, Kim SW, Foissac S, Lipson D, Hart C, Roels S, Borel C, Antonarakis SE, Monaghan AP, John B, Milos PM. Nature. 2010 Jul 29;466(7306):642-6. doi: 10.1038/nature09190.

Sall3 is required for the terminal maturation of olfactory glomerular interneurons.Harrison SJ, Parrish M, Monaghan AP. J Comp Neurol. 2008 Apr 10;507(5):1780-94.

Sall1 regulates mitral cell development and olfactory nerve extension in the developing olfactory bulb. Harrison SJ, Nishinakamura R, Monaghan AP. Cereb Cortex. 2008 Jul;18(7):1604-17.

Abnormal development of zinc-containing cortical circuits in the absence of the transcription factor Tailless. Land PW, Monaghan AP. Brain Res Dev Brain Res. 2005 Aug 8;158(1-2):97-101.

The Tlx gene regulates the timing of neurogenesis in the cortex. Roy K, Kuznicki K, Wu Q, Sun Z, Bock D, Schutz G, Vranich N, Monaghan AP. J Neurosci. 2004 Sep 22;24(38):8333-45.

Loss of the Sall3 gene leads to palate deficiency, abnormalities in cranial nerves, and perinatal lethality. Parrish M, Ott T, Lance-Jones C, Schuetz G, Schwaeger-Nickolenko A, Monaghan AP. Mol Cell Biol. 2004 Aug;24(16):7102-12.

Expression of the transcription factor, tailless, is required for formation of superficial cortical layers. Land PW, Monaghan AP. Cereb Cortex. 2003 Sep;13(9):921-31.

Loss of the tailless gene affects forebrain development and emotional behavior. Roy K, Thiels E, Monaghan AP. Physiol Behav. 2002 Dec;77(4-5):595-600.

A new member of the spalt like zinc finger protein family, Msal-3, is expressed in the CNS and sites of epithelial/mesenchymal interaction. Ott T, Parrish M, Bond K, Schwaeger-Nickolenko A, Monaghan AP.= Mech Dev. 2001 Mar;101(1-2):203-7.

Defective limbic system in mice lacking the tailless gene. Monaghan AP, Bock D, Gass P, Schwäger A, Wolfer DP, Lipp HP, Schütz G. Nature. 1997 Dec 4;390(6659):515-7.


Mark Patterson, Ph.D., M.P.H.
Associate Professor UMKC School of Pharmacy
More info

Research Interests

1) Using mixed methods approaches to examine the prevalence of medication discrepancies and their underlying workflow attributed to those discrepancies that occurring during transitions of care between hospitals and nursing homes in rural Missouri. 2) Proposal currently under review to use the HealthFacts dataset to estimate the prevalence and patterns of antipsychotic polypharmacy prescribing patterns present in patients hospitalized with schizophrenia.


Photo of James B. Reynolds, M.D.
James B. Reynolds, M.D.
Assistant Professor Center for Behavioral MedicinePsychiatry
  • American Academy of Psychiatry and the Law; Midwest Chapter, Member; Program Committee
  • Missouri State Medical Association, State Delegate and Trustee
  • Specialty: Forensic Psychiatry
More info

Dr. Reynolds earned the M.D. degree from the University of Tennessee in 1986. After a tour of duty as a general medical officer and flight surgeon with the U.S. Air Force, he trained in Psychiatry at Wright State University and in Forensic Psychiatry at the Walter Reed Army Medical Center in Washington, D.C. He is Board Certified in General and Forensic Psychiatry. He serves as the Medical Director of the Northwest Missouri Psychiatric Rehabilitation Center in St. Joseph, Missouri, and is Chair of the Forensic Review Committee for the Department of Mental Health for the western half of the State of Missouri. He holds clinical faculty appointments with four nearby medical schools and the Uniformed Services Medical School in Bethesda, Maryland. He has been an active member of the AMA, the APA, and the American Academy of Psychiatry and the Law (AAPL), and served as President of the Midwest Chapter of AAPL in 2013/2014.


Photo of Steven M. Shapiro, M.D., M.H.A.
Steven M. Shapiro, M.D., M.H.A.
Division Director of Child Neurology, CMH, Professor, UMKC School of Medicine Children’s Mercy HospitalDepartment of Neurology, Child Neurology, Clinical Neurophysiology
More info

Education
  • Medical School: University of Pittsburgh School of Medicine
  • Residency: Case Western Reserve University – Pediatrics
  • Fellowship: Children’s Hospital of Pittsburgh – Child Neurology
  • Fellowship: University of Pittsburgh – Auditory Neurophysiology
  • Fellowship: University of Wisconsin – Evoked Potentials
Research Interests

Bilirubin neurotoxicity, kernicterus, neurodevelopmental disorders, auditory neurology, movement disorders, clinical neurophysiology.

For additional information, please click here.

 


Photo of Kim Smolderen, Ph.D.
Kim Smolderen, Ph.D.
Assistant Professor — Implementation Science Department of Biomedical & Health Informatics
  • 2012, Post-Doctoral Fellowship in Outcomes Research PRT: American Heart Association, St. Luke’s Mid-America Heart Institute
  • 2009, PhD in Medical Psychology, Tilburg University, Tilburg Netherlands
More Info

Research Interest

An estimated 8 million individuals in the United States are affected by peripheral arterial disease (PAD), blockages of the leg arteries that can cause excruciating calf pain when walking. PAD can have a major impact on patients’ quality of life. It is also associated with high rates of heart attacks and premature death. While there are a number of treatments, there have been few previous studies that have prospectively examined treatment patterns for PAD or sought to systematically identify opportunities to improve care. Most importantly, there have been no rigorous studies examining the impact of the disease from patients’ perspectives-their symptoms, function, and quality of life-as a function of different patient characteristics and treatments. The PORTRAIT study (Phase II) will systematically document the treatments and health-status outcomes (symptoms, function, and quality of life) of 840 US patients from nine centers over the course of one year to address these gaps in knowledge. It will illuminate whether disparities in treatment or health-status outcomes exist as a function of a patient’s age, gender, race, or socioeconomic or psychological characteristics. As a direct deliverable, it will translate its findings-expected health status changes following PAD treatments over the course of one year-directly to patients through the development of education tools for patients with PAD who need to make a choice with regard to their treatment. As it is PCORI’s mission to assist patients, clinicians, purchasers, and policy makers in making informed health decisions with regard to diseases like PAD, PORTRAIT will substantially elevate the field and identify critical gaps in the way PAD is currently managed, including potential disparities in care, so that the quality of care can be improved. PORTRAIT will also be a critical first step in designing efficient, effective disease management programs for PAD in the future that are based on more personalized and healthcare system-oriented approaches to increase the use of evidence-based guidelines. Finally, as patients have been closely involved in the design of this study in Phase I and continue to be engaged as active advocates and experts on their disease throughout the current study, PORTRAIT will also empower patients and let them decide on what information and outcomes are most relevant for them while dealing with this burdensome condition of PAD.


Photo of Shayla A. Sullivant, M.D.
Shayla A. Sullivant, M.D.
Assistant Professor, University of Missouri-Kansas City Children’s Mercy HospitalPediatrics
More Info

Research Interests

Suicide prevention work; currently working on a tool that screens patients for suicidal thoughts, as well as a parent satisfaction questionnaire.


Photo of John Qiang Wang, M.D., Ph.D.
John Qiang Wang, M.D., Ph.D.
Professor Departments of Anesthesiology & Biomedical Sciences Work M3-225 Work Phone: (816) 235-1907

Westport Anesthesia / Missouri Endowed Chair for Research

  • M.D. Degree: Tongji Medical University, Wuhan, China
  • MS Degree: Tongi Medical University, Wuhan, China
  • Ph.D, Degree: Shanghai Medical University, Shanghai China
  • Fellowship: Beijing Medical University, Beijing China
  • Fellowship: Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee
More info

Biography

John Q. Wang is a Westport Anesthesia/Missouri Endowed Chair in the Department of Anesthesiology and a Professor in the Departments of Anesthesiology and Basic Medical Science at UMKC School of Medicine since 2004. He earned his medical degree in Tongji Medical University in 1982 and his Ph.D. in Shanghai Medical University in 1988. Dr. Wang’s research primarily focuses on drug abuse and addiction. He currently leads a research team supported by NIH grants to conduct animal experiments from molecule to behavior and from in vitro to in vivo. In addition, Dr. Wang is interested in elucidating molecular mechanisms for anesthesia induction.

 

Grants:

NIH R01, DA10355, PI: Qiang Wang, Metabotropic glutamate regulation of amphetamine action, $1,698,750.00, 2013-2018.

NIH R01, MH61469, PI: Qiang Wang, Molecular regulation of metabotropic glutamate receptors in striatal neurons, $1,887,500.00, 2015-2020.

 

Selected Publications

Yang JH, Mao LM, Choe ES, Wang JQ (2017) Synaptic ERK2 phosphorylates and regulates metabotropic glutamate receptor 1 in vitro and in neurons. Mol Neurobiol in press. PMC5410195.

Xue B, Chen EC, He N, Jin DZ, Mao LM, Wang JQ (2017) Integrated regulation of AMPA glutamate receptor phosphorylation in the striatum by dopamine and acetylcholine. Neuropharmacology 112:57-65. PMC5055431.

Mao LM, Wang JQ (2017) Antagonism of dopamine D2 receptors alters phosphorylation of Fyn in the rat medial prefrontal cortex. J Mol Neurosci 61:524-530. PMC5360503.

Mao LM, Wang HH, Wang JQ (2017) Antagonism of muscarinic acetylcholine receptors alters synaptic ERK phosphorylation in the rat forebrain. Neurochem Res42:1202-1210. PMC5405859.

Mao LM, Geosling R, Penman B, Wang JQ (2017) Local substrates of non-receptor tyrosine kinases at synaptic sites in neurons. Acta Physiologica Sinica in press.

 

Presentations:

Faris HJ, He N, Wang JQ. Regulation of Src family kinases in the rat striatum by muscarinic acetylcholine receptors. Great Plains Honors Council Conference, Beaumont, TX, March 31-April 2, 2017.

Faris HJ, Mao LM, Wang JQ. Muscarinic acetylcholine receptors inhibit Src family kinase phosphorylation in the rat striatum. Health Sciences Student Research Summit. University of Missouri Kansas City, Kansas City, MO, April 26, 2017.

 

 

All Research Topics

Resources

The School of Medicine is committed to supporting and expanding research opportunities, as these efforts are key to solving many health care conditions and issues. The school has received significant funding for its research – including many National Institutes of Health-funded projects – involving more than 70 faculty members. The school also supports opportunities for students, who work closely with faculty research mentors, as well as residents and fellows looking to embrace research as part of their medical careers. In addition, the school works with members of the local community participating in research studies, recognizing their valuable contribution to improved medicine and wellness. At UMKC, research is central to its mission of fostering excellence and innovation in medical care.